# A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations

Study · id `cardio:ct-nct07612657` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07612657](<https://clinicaltrials.gov/study/NCT07612657>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07612657

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07612657. Randomized; triple masking; primary purpose treatment. Start 2026-05-29 (anticipated); primary completion 2028-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07612657, source copy `cardio:ctgov-nct07612657-2026-05-29`, retrieved 2026-10-31)
- Planned start: 2026-05-29 (anticipated) (ClinicalTrials.gov record NCT07612657, source copy `cardio:ctgov-nct07612657-2026-05-29`, retrieved 2026-10-31)
- Primary completion: 2028-05-31 (anticipated) (ClinicalTrials.gov record NCT07612657, source copy `cardio:ctgov-nct07612657-2026-05-29`, retrieved 2026-10-31)
- Completion: 2029-11-30 (anticipated) (ClinicalTrials.gov record NCT07612657, source copy `cardio:ctgov-nct07612657-2026-05-29`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07612657-2026-05-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
- Acronym: TRANSCEND
- Condition: Pulmonary Arterial Hypertension
- Condition: Pulmonary Arterial Hypertension (PAH)
- Condition: Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Condition: Pulmonary Arterial Hypertension PAH
- Condition: Pulmonary Arterial Hypertension WHO Group I
- Intervention (Drug): VI-0106
- Intervention (Drug): Placebo
- Lead sponsor: VIVUS LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: a2a3f83f112c438c4d89789cd9e0678777f4824c95c03071909547f789264f55
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
